Catalyst Pharmaceuticals director equity cashed out in merger
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CATALYST PHARMACEUTICALS, INC. director Donald A. Denkhaus reported disposing of 498,773 shares of common stock at $31.50 per share on July 15, 2026, in a disposition to the issuer completed in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. (the Merger).
On the same date, all reported restricted stock units and stock options, covering additional shares of common stock, were cancelled and converted into rights to receive cash payments based on the $31.50 per-share merger consideration, and his reported holdings in these securities fell to 0.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 33,500 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 30,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 20,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 15,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 29,524 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 23,248 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 18,115 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 1,414 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 1,894 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 5,468 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 498,773 | $31.50 | $15.71M |
Footnotes (6)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option was fully vested.
- F6. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Key Terms
restricted stock unit financial
stock option financial
Disposition to issuer financial
Merger financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Donald A. Denkhaus report in the Catalyst Pharmaceuticals (CPRX) Form 4?
How many Catalyst Pharmaceuticals (CPRX) securities does Donald A. Denkhaus report holding after these transactions?
How were restricted stock units treated for Donald A. Denkhaus in the Catalyst (CPRX) Merger?
How were stock options treated for Donald A. Denkhaus in the Catalyst Pharmaceuticals (CPRX) Merger?
Were the reported Catalyst (CPRX) Form 4 transactions made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.